Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Akouos is raising $105,065,001.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Emmanuel Simons played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Akouos

Akouos is building the leading gene therapy company focused on hearing disorders. Our objectives are to restore the inner ear’s ability to produce functional proteins required for hearing, rejuvenate structures of the hearing circuit critical for high-fidelity signal transduction and inner ear homeostasis, and reinforce healthy hearing with local, enduring protein production to protect against drug, noise, and age associated ototoxicity.

To learn more about Akouos, visit http://www.akouos.com/

Contact:
Emmanuel Simons, President and Chief Executive Officer
857-245-5715
https://www.linkedin.com/in/mannysimons/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved